Send to

Choose Destination
J AIDS Clin Res. 2012;S8:3. Epub 2012 Mar 22.

Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.

Author information

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK ; The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.


Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the induction by active vaccination of antibodies that can potently neutralize a broad range of circulating virus strains is a goal not yet achieved, despite more than 2 decades of research. Here we review progress made in the field, from early empirical studies to today's rational structure-based vaccine antigen design. We discuss the existence of broadly neutralizing antibodies, their implications for epitope discovery and recent progress made in antigen design. Finally, we consider the relationship between antigenicity and immunogenicity for B cell recognition and antibody production, a major hurdle for rational vaccine design to overcome.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center